Search
Check Out Our Sponsors
Latest topics
Acetyl L Carnitine as a precursor of AcetylCholine - Depression
Page 1 of 1
Acetyl L Carnitine as a precursor of AcetylCholine - Depression
Those, like myself, with mood disorders should stay away from Acetyl L Carnitine:
MOOD DEPRESSING/DEPRESSION-INDUCING EFFECTS OF CHOLINOMIMETICS
Probably the most convincing evidence that acetylcholine is involved in the regulation of the affective disorders is the observation that centrally active cholinomimetic drugs rapidly induce depressed moods. In addition to observations of depression-induction caused by DFP (100) and cholinomimetic insecticides (34), Janowsky et al. found induction and/or intensification of depressive symptoms in actively ill bipolar manic patients given physostigmine, as well as a worsening of depression in groups of unipolar depressed and schizoaffective depressed patients (45). Similarly, Davis et al. (17) and Modestin et al. (73, 74) demonstrated an increase in depression in manic patients given physostigmine. In addition, Risch et al. (99) and Nurnberger et al. (78, 80) found that depressed patients given the direct cholinergic agonist arecoline also developed depression and other forms of negative affect, including hostility and anxiety. Physostigmine also caused a depressed mood in a majority of euthymic bipolar patients maintained on lithium (84). Risch et al. (95, 98, 99) found a statistically significant increase in self- and observer-rated negative affect on the Brief Psychiatric Rating Scale (BPRS), Profile of Mood States (POMS), and the Activation-Inhibition Rating Scales in normals receiving intravenous physostigmine or arecoline. Likewise, Mohs et al. (75) reported severe depression occurring in Alzheimer's patients receiving the cholinergic agonist oxotremorine. El-Yousef et al (28) reported that normals, having smoked marijuana, became profoundly depressed after receiving physostigmine, an effect that was atropine reversible.
Evidence supportive of a role for acetylcholine in the phenomenology of affective disorders also comes from descriptions of the anergic-inhibitory behavioral effects, as opposed to the mood effects of centrally acting cholinesterase inhibitors and cholinergic agonists. These drugs induce a psychomotor retardation that is very similar to that occurring in endogenous depression. Thus, Rowntree et al. (100) and Modestin et al. (73, 74), studying normals, depressives, and manics, and Gershon and Shaw (34), observing normals, all reported that cholinesterase inhibitors exerted anergic and behavioral-inhibitory effects, as did Janowsky et al (45) in their physostigmine-treated subjects.
Depressed moods have also been observed in subjects receiving acetylcholine precursors, including deanol, choline, and lecithin. Davis et al. (18) and Tamminga et al. (117) found that depressive symptoms occurred in some schizophrenic patients who were treated with choline, a phenomenon that was atropine-reversible. In a subgroup of cases, it was noted that depressed mood was a side effect of choline and lecithin treatments employed to try to reverse the memory deficits of Alzheimer's Disease (117). Also, Casey (9) observed that a depressed mood and, in some cases, a paradoxical hypomania occurred in some deanol-treated tardive dyskinesia and other movement-disorder patients. Thus, precursors of acetylcholine may induce a depressed mood, a finding that is consistent with the adrenergic-cholinergic imbalance hypothesis.
http://www.acnp.org/g4/GN401000095/CH.html
MOOD DEPRESSING/DEPRESSION-INDUCING EFFECTS OF CHOLINOMIMETICS
Probably the most convincing evidence that acetylcholine is involved in the regulation of the affective disorders is the observation that centrally active cholinomimetic drugs rapidly induce depressed moods. In addition to observations of depression-induction caused by DFP (100) and cholinomimetic insecticides (34), Janowsky et al. found induction and/or intensification of depressive symptoms in actively ill bipolar manic patients given physostigmine, as well as a worsening of depression in groups of unipolar depressed and schizoaffective depressed patients (45). Similarly, Davis et al. (17) and Modestin et al. (73, 74) demonstrated an increase in depression in manic patients given physostigmine. In addition, Risch et al. (99) and Nurnberger et al. (78, 80) found that depressed patients given the direct cholinergic agonist arecoline also developed depression and other forms of negative affect, including hostility and anxiety. Physostigmine also caused a depressed mood in a majority of euthymic bipolar patients maintained on lithium (84). Risch et al. (95, 98, 99) found a statistically significant increase in self- and observer-rated negative affect on the Brief Psychiatric Rating Scale (BPRS), Profile of Mood States (POMS), and the Activation-Inhibition Rating Scales in normals receiving intravenous physostigmine or arecoline. Likewise, Mohs et al. (75) reported severe depression occurring in Alzheimer's patients receiving the cholinergic agonist oxotremorine. El-Yousef et al (28) reported that normals, having smoked marijuana, became profoundly depressed after receiving physostigmine, an effect that was atropine reversible.
Evidence supportive of a role for acetylcholine in the phenomenology of affective disorders also comes from descriptions of the anergic-inhibitory behavioral effects, as opposed to the mood effects of centrally acting cholinesterase inhibitors and cholinergic agonists. These drugs induce a psychomotor retardation that is very similar to that occurring in endogenous depression. Thus, Rowntree et al. (100) and Modestin et al. (73, 74), studying normals, depressives, and manics, and Gershon and Shaw (34), observing normals, all reported that cholinesterase inhibitors exerted anergic and behavioral-inhibitory effects, as did Janowsky et al (45) in their physostigmine-treated subjects.
Depressed moods have also been observed in subjects receiving acetylcholine precursors, including deanol, choline, and lecithin. Davis et al. (18) and Tamminga et al. (117) found that depressive symptoms occurred in some schizophrenic patients who were treated with choline, a phenomenon that was atropine-reversible. In a subgroup of cases, it was noted that depressed mood was a side effect of choline and lecithin treatments employed to try to reverse the memory deficits of Alzheimer's Disease (117). Also, Casey (9) observed that a depressed mood and, in some cases, a paradoxical hypomania occurred in some deanol-treated tardive dyskinesia and other movement-disorder patients. Thus, precursors of acetylcholine may induce a depressed mood, a finding that is consistent with the adrenergic-cholinergic imbalance hypothesis.
http://www.acnp.org/g4/GN401000095/CH.html
Hoople- Posts : 44
Join date : 2010-09-24
Similar topics
» Question for CS: Acetyl-L-Carnitine vs L-Carnitine tartrate
» Acetyl L Carnitine vs. : Carnitine Fumarate, which one is the best?
» Acetyl-L-Carnitine
» Acetyl L-Carnitine HCI
» Acetyl L Carnitine
» Acetyl L Carnitine vs. : Carnitine Fumarate, which one is the best?
» Acetyl-L-Carnitine
» Acetyl L-Carnitine HCI
» Acetyl L Carnitine
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
|
|
Fri May 17, 2024 7:01 am by Atlas
» zombie cells
Sat May 11, 2024 6:54 am by CausticSymmetry
» Sandalore - could it be a game changer?
Wed May 08, 2024 9:45 pm by MikeGore
» *The first scientific evidence in 2021 that viruses do not exist*
Tue May 07, 2024 4:18 am by CausticSymmetry
» China is at it again
Tue May 07, 2024 4:07 am by CausticSymmetry
» Ways to increase adult stem cells
Mon May 06, 2024 5:40 pm by el_llama
» pentadecanoic acid
Sun May 05, 2024 10:56 am by CausticSymmetry
» Exosome Theory and Herpes
Fri May 03, 2024 3:25 am by CausticSymmetry
» Road to recovery - my own log of everything I'm currently trying for HL
Tue Apr 30, 2024 1:55 pm by JtheDreamer